Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AGAgomAb Therapeutics N.V. logo

AgomAb Therapeutics N.V. (AGMB)

NASDAQ Global Market · Currency in USD
$9.05 ▼ -0.21 (-2.27%)
At close: Oct 23, 4:00 PM ET. Market closed.
$9.05 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:59 PM ET

Summary

Previous Close
$9.26
Open
$9.15
Day's Range
$8.68 – $9.18
52 Week Range
$7.92 – $17.82
Volume
49,125
Avg. Volume
127,567
Market Cap
$445.69M
Beta (5Y Monthly)
1.80
PE Ratio (TTM)
--
EPS (TTM)
-$0.73
Earnings Date
Mar 3, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$35.00

Profile: AgomAb Therapeutics N.V.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
62
CEO
Tim Knotnerus
Website
agomab.com

AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials.

Earnings

Next report: Wed, Mar 3, 2027
EPS estimate -$0.95
DateEst.Actual
Aug 6, 2026$1.18-$0.91Miss
Apr 23, 2026-$0.52-$45.69Miss
Feb 25, 2026-$0.52-$0.36Beat

Analyst view

Consensus price target
$35.00 ▲ +286.7%
Range $35.00 – $35.00

Get free alerts on AGMB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.